- Home
- TENB vs KNSA Comparison
TENB vs KNSA Comparison
Compare TENB & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | KNSA |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 3.4B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TENB | KNSA |
|---|---|---|
| Price | $20.38 | $47.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | $34.70 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 3.4M | 515.3K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | ★ $999,405,000.00 | $677,564,000.00 |
| Revenue This Year | $9.37 | $35.71 |
| Revenue Next Year | $7.04 | $17.13 |
| P/E Ratio | ★ N/A | $60.26 |
| Revenue Growth | 11.04 | ★ 60.09 |
| 52 Week Low | $17.28 | $18.26 |
| 52 Week High | $38.54 | $49.12 |
Technical Indicators
Market Signals| Indicator | TENB | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 59.51 |
| Support Level | $19.15 | $40.47 |
| Resistance Level | $23.33 | $49.12 |
| Average True Range (ATR) | 1.20 | 2.15 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 53.49 | 72.69 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.